Saracatinib

Generic Name: Saracatinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₂ClN_₅O_₅

CAS Number: 379231-04-6

Unique Ingredient Identifier: 9KD24QGH76

Background: Saracatinib has been investigated for the treatment of Cancer, Osteosarcoma, Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Saracatinib in Treating Patients With Prostate Cancer

Phase 2

Terminated

Conditions: Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions: Other: hydrocortisone/placebo
Drug: saracatinib

First Posted Date: 2010-12-28

Last Posted Date: 2015-04-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT01267266

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States

and more 12 locations

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: saracatinib
Other: pharmacogenomic studies
Other: pharmacological study
Procedure: positron emission tomography
Radiation: fludeoxyglucose F 18
Other: laboratory biomarker analysis

First Posted Date: 2008-08-15

Last Posted Date: 2019-04-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT00735917

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇺🇸
University of Colorado at Denver, Aurora, Colorado, United States

and more 6 locations

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

Phase 2

Terminated

Conditions: Recurrent Thymoma and Thymic Carcinoma
Stage IVA Thymoma
Invasive Thymoma and Thymic Carcinoma
Stage III Thymoma
Stage IVB Thymoma

Interventions: Drug: saracatinib

First Posted Date: 2008-07-21

Last Posted Date: 2015-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00718809

Locations: 🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IIA Melanoma
Stage IIB Melanoma
Stage IIC Melanoma
Stage IV Melanoma

Interventions: Drug: saracatinib

First Posted Date: 2008-04-29

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00669019

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Adult Fibrosarcoma
Adult Leiomyosarcoma
Adult Liposarcoma
Adult Malignant Fibrous Histiocytoma
Adult Rhabdomyosarcoma
Dermatofibrosarcoma Protuberans
Endometrial Stromal Sarcoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Uterine Sarcoma
Stage III Adult Soft Tissue Sarcoma

Interventions: Drug: saracatinib

First Posted Date: 2008-04-16

Last Posted Date: 2018-06-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00659360

Locations: 🇺🇸
Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
🇨🇦
Montreal General Hospital, Montreal, Quebec, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

and more 1 locations

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy

Phase 2

Completed

Conditions: Stage IV Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: saracatinib

First Posted Date: 2008-03-19

Last Posted Date: 2018-08-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00638937

Locations: 🇨🇦
McGill University Department of Oncology, Montreal, Quebec, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
The Ottawa Hospital Cancer Centre (Ottawa Health Research Institute) Civic Campus, Ottawa, Ontario, Canada

and more 1 locations

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Adenocarcinoma of the Stomach
Recurrent Gastric Cancer
Stage III Gastric Cancer
Stage IV Esophageal Cancer
Stage III Esophageal Cancer
Stage IV Gastric Cancer

Interventions: Drug: saracatinib

First Posted Date: 2008-02-06

Last Posted Date: 2018-08-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00607594

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

and more 2 locations

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Stage IIIC Breast Cancer
Stage IV Breast Cancer
Male Breast Cancer
Progesterone Receptor-negative Breast Cancer
Recurrent Breast Cancer
Estrogen Receptor-negative Breast Cancer
Stage IIIB Breast Cancer

Interventions: Drug: saracatinib
Other: laboratory biomarker analysis

First Posted Date: 2007-11-16

Last Posted Date: 2014-04-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00559507

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Malignant Pleural Effusion
Extensive Stage Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Lung Metastases

Interventions: Drug: saracatinib

First Posted Date: 2007-09-12

Last Posted Date: 2017-12-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00528645

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Completed

Conditions: Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer

Interventions: Drug: saracatinib
Other: laboratory biomarker analysis

First Posted Date: 2007-08-08

Last Posted Date: 2018-04-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00513071

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy